Company News 

Trading in line for Dechra

Trading in line for Dechra

Dechra Pharmaceuticals (DPH) achieved full-year revenue growth of 7 per cent for the year to June – in line with bosses’ expectations, but slightly below the estimate of 9 per cent projected by brokers Jefferies and Stifel. The latter has reduced its sales estimates by 2.3 per cent and 2.5 per cent for the 2020 and 2021 respectively, to £513m and £559m. Still, analysts here have left their earnings per share forecasts unchanged – citing improving margins.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now